SEC Tracker
Get the app

GeneDx Holdings WGS

GeneDx reports Q3 2026 results

GeneDx Holdings (WGS) filed an 8-K with the SEC on Nov 9, 2026, 4:11 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Revenue of $123.1 million
  2. Exome and genome revenue of $110.4 million
  3. Adjusted net income of $8.6 million
  4. Exome and genome volume growth of 25%

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when GeneDx Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.